VIVEbiotech: 2025 Lentiviral Vector Highlights
Reflecting on a year of progress in lentiviral vector development and production.
As 2025 comes to a close, VIVEbiotech is proud to highlight the progress made in developing and producing high-quality lentiviral vectors that support clinical programs worldwide.
Dozens of patients treated by our clients have already benefited from these vectors, with several achieving complete remission.
Our vectors are being used in a wide range of applications, including CAR-T, TCR, NK-CAR therapies, and rare disease programs. Clinical trials using VIVEbiotech-produced vectors are ongoing across Europe, the US, Asia, and Australia, reflecting the global reach and impact of our work.
We remain committed to supporting our partners with cutting-edge development and manufacturing capabilities, helping advance innovative therapies with the potential to transform patients’ lives.
Follow us on LinkedIn to stay updated on our latest news and achievements.